Mysterious US space plane lands on California coast

Washington, Jun 2: There is no place for hate and racism in the society, Microsoft CEO Satya Nadella has said, asserting that empathy and shared understanding are a start, but more needs to be done. Nadella’s remarks come in the wake of the custodial death of George Floyd, a 46-year-old African-American man who was pinned to the ground in Minneapolis on May 25 by a white police officer who kneeled on his neck as he gasped for breath.

“There is no place for hate and racism in our society. Empathy and shared understanding are a start, but we must do more,” Nadella said in a tweet on Monday.

“I stand with the Black and African American community and we are committed to building on this work in our company and in our communities,” Nadella said.

A day earlier, Google CEO Sunder Pichai expressed solidarity with the African-American community.

“Today on US Google & YouTube homepages we share our support for racial equality in solidarity with the Black community and in memory of George Floyd, Breonna Taylor, Ahmaud Arbery & others who don’t have a voice,” Pichai wrote on Twitter on Sunday.

“For those feeling grief, anger, sadness & fear, you are not alone,” Pichai said, sharing a screenshot of the Google search home page which said, “We stand in support of racial equality, and all those who search for it.”

Nadella’s Microsoft also said they will be using the platform to amplify voices from the Black and African American community at the company.

Nadella had also spoken out a few months ago about the discriminatory Citizenship Amendment Act passed in his native country. Talking to BuzzFeed’s editor-in-chief, Ben Smith, in Manhattan, Nadella said what’s happening in the country is “sad.”

“I think what is happening is sad. I feel, and in fact quite frankly, now being informed (and) shaped by the two amazing American things that I’ve observed which is both, it’s technology reaching me where I was growing up and its immigration policy and even a story like mine being possible in a country like this.

“I think, it’s just bad, if anything, I would love to see a Bangladeshi immigrant who comes to India and creates the next unicorn in India or becomes the CEO of Infosys. That should be the aspiration. If I had to sort of mirror what happened to me in the US, I hope that’s what happens in India,” Microsoft’s India-born CEO was quoted as saying by BuzzFeed.

Paris, Apr 10: French pharma major Sanofi said on Friday it has decided to donate 100 million doses of hydroxychloroquine, the anti-malaria drug which could be a potential weapon against novel coronavirus, across 50 countries.

The company has already doubled its incremental production capacity on top of the usual production for current indications across its eight hydroxychloroquine manufacturing sites worldwide and is on track to quadruple it by the summer.

"In this global health emergency, Sanofi stands ready to assist as many countries as possible, starting with countries where its medicine is registered for current approved indications as well as countries where there are no hydroxychloroquine suppliers or countries with underserved populations," it said in a statement.

Sanofi called for coordination among the entire hydroxychloroquine chain worldwide to ensure the continued supply of the medicine if proven to be a well-tolerated and effective treatment in COVID-19 patients.

"The COVID-19 pandemic is an unprecedented health and economic crisis which is shaking some of the very fundamentals of international solidarity and cooperation among countries," said Chief Executive Officer Paul Hudson. "This virus does not care about the concept of borders, so we should not either," he added.

"It is critical that international authorities, local governments, manufacturers and all other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it. If the trials prove positive, we hope our donation will play a critical role for patients," said Hudson.

While hydroxychloroquine is generating a lot of hope for patients around the world, said Sanofi, it should be remembered that there are no results from ongoing studies and the results may be positive or negative.

To date, there is insufficient clinical evidence to draw any conclusion over the safety and efficacy of hydroxychloroquine in the management of COVID-19 patients.

It is one of several medicines being investigated by the World Health Organisation (WHO) in its international clinical trial seeking a treatment solution for COVID-19. "Sanofi is supporting ongoing trials by providing the medicine to some participating investigator sites and other independent research centres," it said.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.